A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder
International Journal of Neuropsychopharmacology, 05/21/2012Alvarez E et al.
In this study, treatment with 5 mg and 10 mg Lu AA21004 for 6 wk was efficacious and well tolerated in patients with major depressive disorder.
In this 6–wk, multi–site study, 429 patients were randomly assigned (1:1:1:1) to 5 or 10 mg Lu AA21004, placebo or 225 mg venlafaxine XR.
All patients had a baseline Montgomery–Asberg Depression Rating Scale (MADRS) total score ≥30.
The primary efficacy analysis was based on the MADRS total score adjusting for multiplicity using a hierarchical testing procedure starting with the highest dose vs. placebo.
Lu AA21004 was statistically significantly superior to placebo (n=105) in mean change from baseline in MADRS total score at week 6 (p<0.0001, last observation carried forward), with a mean treatment difference vs. placebo of 5.9 (5 mg, n=108), and 5.7 (10 mg, n=100) points.
Venlafaxine XR (n=112) was also significantly superior to placebo at week 6 (p<0.0001).
In total, 30 patients withdrew due to adverse events (AEs) – placebo: four (4%); 5 mg Lu AA21004: three (3%); 10 mg Lu AA21004: seven (7%); and venlafaxine: 16 (14%).
The most common AEs were nausea, headache, hyperhidrosis, and dry mouth.
No clinically relevant changes over time were seen in the clinical laboratory results, vital signs, weight, or ECG parameters.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.